Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen reported Q4 revenue of $225.3M (down 0.1% reported; +4.3% core growth), with Food Safety revenue rising to $166.8M (+5.8% core) and adjusted EBITDA growing 12% to $45.4M (20.2% margin, +220 bps YoY). The company raised its FY2027 outlook to $880M–$885M revenue and $180M–$182M adjusted EBITDA, while planning a 50% jump in R&D and $25M of transformation investment, even as it expects macro near-term headwinds from inflation pressures linked to the Iran war. Liquidity/credit improves post-genomics: $140M net proceeds are targeted for debt reduction to reach ~2.5x net leverage, and management highlighted inventory down >$36M and a 40% improvement in on-time/full delivery as key execution wins.

Analysis

The market should view this as a credibility-reset story first and a growth story second. The near-term equity setup is driven less by the modest top-line guide and more by the combination of improving service levels, inventory release, and a cleaner balance sheet path; that supports a higher multiple even before the R&D spend pays off. If management executes, the biggest second-order winner is the company’s own pricing power: better fill rates and a broader enterprise-sales motion should let it take share from smaller, more fragmented testing suppliers that cannot match breadth or reliability.

The main nuance is that a lot of the margin improvement is not from demand inflection but from operational repair. That means the first real confirmation points are August SKU validation, the November transfer start, and the fall Investor Day, not the next quarterly print. If those milestones slip, the market will likely reclassify the current improvement as timing rather than structural; the thesis is most vulnerable if gross margin stalls below the high-40s or if inventory reductions reverse as transition complexity rises.

Over 6-18 months, the setup becomes more interesting because duplicated manufacturing costs should roll off while automation and S&OP gains compound. The contrarian point is that consensus may be underestimating the option value in the balance sheet cleanup: the genomics proceeds plus free cash flow can push leverage toward a level where NEOG can both fund innovation and de-risk equity duration. The flip side is that the 50% R&D increase is a 2029 story, so investors paying for future product cycles today are assuming flawless execution across a long bridge.

I would frame this as a tactical long on pullbacks rather than chasing strength. For now, the best risk/reward is the execution path between now and the fall investor event, where each milestone can expand the multiple if it de-risks the margin bridge.

Key Decisions for Investors

• Go long NEOG on post-earnings weakness; use a 1-3 month horizon into the August Petrifilm validation and fall Investor Day. Falsify if management misses the validation milestone or signals transition slippage.
• Structure NEOG call spreads rather than outright calls for the next catalyst window; the stock likely rerates on execution, but upside is capped by the fact that FY27 is still an investment year.
• Add to NEOG only if gross margin holds near the high-40s and working capital stays positive in the next print; those are the cleanest proofs that the turnaround is structural, not one-quarter noise.
• Watch NEOG vs. a food-safety quality proxy basket; if you cannot source a clean peer, stay single-name. The thesis is company-specific and should not be diluted into a broad sector bet.
• Reduce/exit the long if the genomics divestiture approval drifts or if net leverage fails to trend toward the low-3x area by year-end; the de-risking story is part of the multiple support.